Additionally, significant differences were observed in stromal score, immune score, and ESTIMATEScore between high CD58 and low CD58 groups in WHO grade II and III gliomas (p < .001), while no difference was observed in WHO grade IV gliomas (p > .05), as shown in Figure 4D. Here, CD58 is linked to central nervous system cancer.